A review of trial data shows that an experimental skin patch for treating attention-deficit hyperactivity disorder (ADHD) is effective, the patch's maker Noven Pharmaceuticals Inc. April 1.
Miami-based Noven said it expects to use data from the phase 3 clinical trial of the MethyPatch transdermal patch to file a new drug application with the US Food and Drug Administration this summer. The patch delivers the drug Ritalin, or methylphenidate, throughout the day, through the skin.
The trial, involving over 200 patients between the ages of 6 and 12, measured teacher ratings of patient attention and behavior using a standard rating scale. By this measure, Noven said MethyPatch offered highly statistically significant improvement in patient attention and behavior compared to placebo.
If approved by the FDA, Noven said it expects MethyPatch will reach the US market in the second half of 2003, and that it will be the first transdermal therapy available for ADHD. All presently approved ADHD medications are delivered orally.
Noven April 1, 2002
This must be some perverse April Fool's joke.
ADHD is characterized by developmentally inappropriate impulsivity, inattention and hyperactivity and affects 3% to 5% of school-age children. Over 1.5 million children are currently on ADHD medication.
This new patch will only serve to increase the number of children on inappropriate medication.
Clearly, the first step in improving children with ADHD is to have them follow the eating plan. The high amounts of sugars, breads, cereals, juices, and sodas are frequently one of the most significant factors contributing to the ADHD.
If you have a child with ADHD you will also want to read the interview we did with the recently deceased Dr. Lendon Smith on this subject.
Related Articles:
Non-Drug Treatment of ADD/ADHD